Identification of a gain-of-function stat3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome

Blood

Volumn 127, Issue 7, 2016, Pages 948-951

  Walker, Sarah ^a   Wang, Chen ^b   Walradt, Trent ^b   Hong, Bok Sil ^b   Tanner, Justin R ^c   Levinsohn, Jonathan L ^b   Goh, Gerald ^d   Subtil, Antonio ^b   Lessin, Stuart R ^e   Heymann, Warren R ^f,g   Vonderheid, Eric C ^h   King, Brett A ^b   Lifton, Richard P ^b,i,j   Choi, Jaehyuk ^b,c,i  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Cooper Medical School of Rowan University ^*  (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ Howard Hughes Medical Institute ^*  (United States)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 5; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ADULT; CASE REPORT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CYTOKINE PRODUCTION; DISEASE DURATION; DNA SEQUENCE; EOSINOPHILIA; FEMALE; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HYPEREOSINOPHILIC SYNDROME; LABORATORY TEST; LETTER; LYMPHOCYTIC VARIANT HYPEREOSINOPHILIC SYNDROME; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SOMATIC MUTATION; AMINO ACID SUBSTITUTION; GENETICS; MISSENSE MUTATION; PATHOLOGY;

ADULT; AMINO ACID SUBSTITUTION; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MUTATION, MISSENSE; STAT3 TRANSCRIPTION FACTOR;

EID: 84959422862     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-654277     Document Type: Letter

References (17)

1. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):389-413.
2. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol. 2014;89(3): 325-337.
3. Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011-1019.
4. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15): 3048-3057.
5. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20): 1905-1913.
6. Pilati C, Amessou M, Bihl MP, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208(7): 1359-1366.
7. Crescenzo R, Abate F, Lasorsa E, et al; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium "Genetics-Driven Targeted Management of Lymphoid Malignancies." Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma [published correction appears in Cancer Cell. 2015;27(5):744]. Cancer Cell. 2015;27(4):516-532.
8. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127): 1546-1558.
9. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005;33(Suppl 1): D514-D517.
10. Kwon H, Thierry-Mieg D, Thierry-Mieg J, et al. Analysis of interleukin-21- induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity. 2009;31(6):941-952.
11. Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-b signalling. Nature. 2010;467(7318): 967-971.
12. Chen X, Xu H, Yuan P, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133(6): 1106-1117.
13. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43): 15545-15550.
14. Stritesky GL, Muthukrishnan R, Sehra S, et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity. 2011;34(1): 39-49.
15. Kanhere A, Hertweck A, Bhatia U, et al. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun. 2012;3:1268.
16. Bendell JC, Hong DS, Burris HA III, et al. Phase 1, open-label, doseescalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 74(1):125-130.
17. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014; 46(8):812-814.